Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) is indicated for active immunization of infants, children and adolescents from 6 weeks through 17 years of age (prior to the 18^th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) is indicated for active immunization of infants, children and adolescents from 6 weeks through 17 years of age (prior to the 18^th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

Relevant warnings and precautions:

• Immunocompromised individuals may have a reduced antibody response to the vaccine.
• Safety and immunogenicity data on Prevnar 20 are not available for individuals in certain immunocompromised groups (e.g., those with malignancy or nephrotic syndrome) and vaccination should be considered on an individual basis. Some safety and immunogenicity data are available in individuals with sickle cell disease, HIV infection, or hematopoietic stem cell transplant.
• The administration of Prevnar 20 should be postponed in individuals with acute severe febrile illness.
• As with any intramuscular injection, Prevnar 20 should be given with caution in individuals with thrombocytopenia or any coagulation disorder, or receiving anticoagulant therapy.
• May not protect all individuals from pneumococcal disease.

For more information:

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available on request by calling 1-800-463-6001.

Prevnar 13 is indicated for active immunization of infants and children from 6 weeks to 5 years of age (prior to the 6^th birthday) for the prevention of pneumonia and invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

Relevant warnings and precautions:

• Immunocompromised individuals may have a reduced antibody response to the vaccine.
• Safety and immunogenicity data on Prevnar 13 are not available for individuals in certain immunocompromised groups (e.g., those with malignancy or nephrotic syndrome) and vaccination should be considered on an individual basis. Some safety and immunogenicity data are available in individuals with sickle cell disease, HIV infection, or hematopoietic stem cell transplant.
• The administration of Prevnar 13 should be postponed in individuals with acute severe febrile illness.
• As with any intramuscular injection, Prevnar 13 should be given with caution in individuals with thrombocytopenia or any coagulation disorder, or receiving anticoagulant therapy.
• May not protect all individuals from pneumococcal disease.

For more information:

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available on request by calling 1-800-463-6001.